The aim of this nonsystematic review is to provide an overview about the latest and most relevant data in literature about the role of PSMA ligand PET tracers in the management of prostate cancer, exploring the settings of staging, biochemical recurrence (BCR) and castrate-resistant prostate cancer (CRPC). This evidence concerns the gene FOLH1 and prostate cancer.